Janus Henderson Investors — Full Portfolio

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.

BiotechHealthtechMedical DevicesBoston, US

TFTodd Foley(Co-founder and Chairman)inPBPatrick Baeuerle(Co-founder & Advisor)inSRShulamit Ron-Bigger(Executive Officer)inKDKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPLPaul L. Feldman(Chief Scientific Officer)in

Co-investorsANAndreessen HorowitzECEcoR1 CapitalMPMPM BioImpactMRMRL Ventures FundPAPappas CapitalRARA Capital+5 more

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

GWGarrett Winslow(Executive Officer)inLFLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsACAccess BiotechnologyBABAM ElevateBABay City CapitalCOCommodore CapitalEIEIR VenturesFOForbion+6 more

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesFOForesite CapitalFRFrazier Life SciencesOROrbiMed+6 more

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5A5AM VenturesOROrbiMedPFPfizer Venture InvestmentsRORoche Venture FundARARCH Venture PartnersBABay City Capital+2 more

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)ALAlexandria+8 more

Monopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder.

BiotechHealthtechMedical DevicesLake Forest, US

CDChandler D. Robinson(Executive Officer, Director, Promoter)inCMChristopher M. Starr(Executive Officer, Director)Andrew P. Mazar(Executive Officer, Director)

BoardMichael J. Brown(Director)

Co-investorsRARA Capital

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPFOForesite CapitalFRFrazier Life SciencesGEGeneral CatalystNENextech Invest+8 more

Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies.

BiotechDeep TechHealthtechVenice, US

LSLawrence Steinman(Director)TRTiago Reis Marques(Chief Executive Officer)inIsrael Maxx Abramowitz(Executive Officer, Director)Craig Auringer(Executive Officer, Director)

Co-investorsVIVivo Capital

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEOEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBIBioAdvanceBABAM ElevateBRBraidwellCOCommodore CapitalOROrbiMedRARA Capital+2 more

BiotechSouth San Francisco, US

Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesLOLongitude CapitalMEMedicxi+4 more

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

GPGrant Pickering(Founder)inGEGrant E. Pickering(Chief Executive Officer and Director)in

Co-investorsBIBioRock VenturesCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesLOLongitude CapitalPIPivotal Life Sciences+2 more

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.

BiotechHealthtechMedical DevicesAustin, US

Shanshan Xu(Founder & Chief Executive Officer)inHJHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCMCrystal MacKay(Chief Operating Officer)in

Co-investorsININCE CapitalRARA CapitalSASalviaBIBiotechnology Value FundREREDMILE

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

PTPraveen Tipirneni(Chief Executive Officer)LWLiangsu Wang(Chief Scientific Officer)ZLZhong Liu(Chief Technology Officer)APAaron Pelta(Chief Business Officer)CWColm White(Chief Program Officer)

Co-investorsATAtlas VentureLALAVVEvenBio Partners

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

WWWilliam Wei Caoin

Co-investorsLALAVLILilly Asia VenturesOROrbiMedPIPivotal Life SciencesEXExome Asset ManagementRARA Capital+2 more

35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.

BiotechHealthtech

Ilia(CEO)Maureen(CSO)

Co-investorsFRFrazier Life SciencesVEvenBio PartnersVIVivo Capital

AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.

BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US

AIAnar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)

Co-investors1/1/1 CapitalABabrdn plcANAngelini VenturesFIFidelity InvestmentsSASanofi Ventures

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(MD)KLKuo-Shyan Lin(PhD)DPDavid Perrin(PhD)

Co-investorsANAndreessen HorowitzASAscenta CapitalDEDelos CapitalGEGeneral CatalystLILightspeed Venture PartnersLOLongitude Capital+9 more

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Ben Barres(Scientific Co-Founder)DLDouglas Love(Founder)inMark L Smith(Executive Officer)CMCampbell Murray(Director)inThomas Wiggans(Director)RSRicky Sun(Director)

Co-investorsBABain Capital Life SciencesCOCorrelation VenturesNENew Enterprise Associates (NEA)BLBlackRockBLBlackstone Life SciencesCLClarus Ventures+2 more

Apartment List operates an online rental marketplace that uses a quiz-based AI matching system to connect renters with apartments that fit their preferences and lifestyle.

AI & Machine LearningMarketplacesPropTechSan Francisco, US

JDJohn Douglas Kobs II(Executive Officer, Director)Charles Christopher Herndon(Executive Officer, Director)JKJohn Kobs(Founder)inCEChris Erickson(Co-founder)in

BoardJosh Hannah(Director)DSDana Stalder(Director)in

Co-investorsANAndre IguodalaAUAUTHENTIC VENTURESCACanaan PartnersGLGlynn Capital ManagementMAMatrixTETenaya Capital+5 more

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DADAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FZFENG ZHANG(Director)ANNIE HAZLEHURST(Director)

BoardKCKEITH CRANDELL(Director)DRDAVID R. WALT(Director)in

Co-investorsARARCH Venture PartnersILIllumina VenturesONOno Venture Investment, Inc.TCTCG CrossoverALAlly Bridge GroupRERevelation Partners+4 more

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsANAndera PartnersDEDementia Discovery FundM M VenturesNONovartis Venture FundPFPfizer Venture InvestmentsRARA Capital+3 more

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

IDIvana Djuretic(Founder)inAYAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)

Co-investorsEMEmles Venture PartnersGOGoAhead VenturesMIMission Bay CapitalMIMission BiocapitalRARA CapitalY Y Combinator+4 more

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

JWJonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)MTMark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)RKRahul Kakkar(Director)inGreg Bell(Executive Officer)

Co-investorsALAlpha Wave GlobalBIBioBritVEvenBio PartnersREREDMILESASamsara BioCapitalVEvenBio Global Strategic+1 more

Bigfoot Biomedical develops a diabetes management system that combines continuous glucose monitor data with a doctor's instructions to give insulin dose recommendations.

Digital HealthHealthtechMedical DevicesNew York, US

Jeffrey Brewer(Executive Officer, Director)inBryan Mazlish(Executive Officer, Director)inJon Brilliant(Executive Officer)

Co-investorsJDJDRF T1D FundWIWinklevoss CapitalXPXplorer CapitalSMSmile GroupVIVisionnaire Ventures, Llc

Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared.

HealthtechMedical DevicesPleasanton, US

CBChris Buchko(Executive Officer)inDouglas Hughes(Executive Officer, Director)Jee Shin(Executive Officer, Director)inMark Kidd(Executive Officer)Joe Catanese(Executive Officer, Director)

BoardRDRyan Drant(Director)in

Co-investorsQUQuesta CapitalALAlly Bridge Group

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

GCGina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNENextech InvestRERed Tree VentureSASamsara BioCapitalALAlly Bridge GroupPEPerceptive Xontogeny VentureTHThird Rock Ventures

Crypto.com operates a cryptocurrency exchange and digital asset platform serving 150 million users across 90 countries, with a mission to accelerate global adoption of cryptocurrency.

Crypto & Web3Fintech

KMKris Marszalek(Co-Founder & CEO)inRMRafael Melo(Co-Founder & CFO)inBBBobby Bao(Co-Founder, Head of Crypto.com Capital)

Co-investorsMOMoonhill CapitalAVAvalanche FoundationBABalderton CapitalBLBlockchain CapitalBNBNP ParibasBPBpifrance+9 more

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

GSGeorge Simeon(CEO)inGregory S. Curhan(CFO)GDGuy De La Rosa(CMO)in

Co-investorsADAdjuvant CapitalOROrbiMedRARA CapitalSASanofi VenturesHBHBM Healthcare InvestmentsMEMedicxi

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

BiotechHealthtechCambridge, US

Kevin Mills(Executive Officer, Director)inRGRonald Goldstein(Executive Officer)inDCDonald Corcoran(Executive Officer, Director)inMRMarkus Renschler(Director)in

BoardTimothy Romberger(Director)Barry Mills(Director)

Co-investorsDRDroia VenturesLILightstone VenturesOUOUP (Osage University Partners)ALAlly Bridge GroupDEDe Novo VenturesNONovo Holdings+3 more

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)inSWSimon Ward(Chief Scientific Officer & Founder)in

Co-investorsACAccess BiotechnologyCACanaan PartnersSASanofi VenturesSVSV Health InvestorsSRSR One Capital ManagementBRBritish Business Bank

The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.

BiotechHealthtechSan Diego, US

ATArthur T Suckow(Executive Officer)inASArthur Suckow, Ph.D.(Founder)in

Co-investorsACAccess BiotechnologyEXExSight VenturesRARA Capital

Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

Lei Stanley Qi(Scientific Founder)inASAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)

BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)

Co-investorsALAlly Bridge GroupABabrdn plcANAngelini VenturesFIFidelity InvestmentsSASanofi Ventures

Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.

AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US

Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)LMLawrence Mandes(Managing Director, New Markets)in

BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)

Co-investorsSOSofinnova PartnersTETeamworthy VenturesTHThe Colorado Impact FundVTVTF CapitalALAlly Bridge GroupCACatalyst Investors+5 more

Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.

CleantechClimate TechEnergy

VMVeery Maxwell(Founder)in

Co-investorsABABS Capital PartnersBLBlue Haven InitiativeGAGalvanize Climate SolutionsALAlly Bridge GroupFIFidelity InvestmentsGIGilmartin Capital LLC+4 more

Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.

BiotechHealthtechMedical DevicesRedwood City, US

DGDoug Godshall(Executive Officer, Director)inSASteve Anheier(Executive Officer)in

BoardJonathan Waldstreicher(Executive Officer)APAntoine Papiernik(Director)inSeth Harrison(Director)ZSZack Scott(Director)in

Co-investorsNONorwest Venture PartnersALAlly Bridge GroupATATPFIFidelity InvestmentsGIGilmartin Capital LLCPEPerceptive Xontogeny Venture+2 more

IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.

B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US

Ike Nnah(Executive Officer, Director)inDCDavid Coppins(Executive Officer, Director)inPrince Nnah(Director)

Co-investorsEAEastward Capital PartnersENEndeavour VisionEQEquitage Ventures, L.L.C.GEGenerator VenturesKAKaiser Permanente VenturesLOLongitude Capital+3 more

Interleukin operates a B2B platform for sourcing and procuring medical products and services, letting registered buyers discover accredited suppliers, request quotes, send purchase orders, and pay on terms in one system.

B2B MarketplacesHealthtechMedical Devices

Co-investorsBUBuko VenturesDEDeerfield Management Company

Kardium develops the Globe Pulsed Field System, an all-in-one cardiac ablation catheter with 122 individually selectable electrodes that combines high-density mapping and pulsed field ablation.

BiotechHardwareHealthtechMedical DevicesBurnaby

DGDoug Goertzen(Executive Officer)inKCKevin Chaplin(Executive Officer, Director)in

BoardManuel Alba-Marquez(Director)Ian Ihnatowycz(Director)Armos Michelson(Director)David Rosa(Director)

Co-investorsGRGranada FundsECEckuityFIFidelity InvestmentsQAQatar Investment Authority

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)MRMichael Rome(Director)in

Co-investorsFOForesite CapitalNENextech InvestRARA CapitalVEVenrock Healthcare Capital PartnersVIViking Global Investors

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

AWAetna Wun Trombley(President and CEO)inABAmy Bachrodt(Chief Financial Officer)inCLChin Lee(Chief Medical Officer)inSSSteve Staben(Chief Scientific Officer)inSTSofia Touami(Chief Business Officer)inKFKaren Flick(General Counsel)in

Co-investorsREREDMILEVEVersant VenturesBABAM ElevateFRFranklin TempletonHBHBM Healthcare InvestmentsINInvus+4 more

Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.

HardwareHealthtechMedical DevicesSeattle, US

Gregory J Bullington(Executive Officer, Director)RPRichard Patton(Co-founder)

BoardPaul Meister(Director)

Co-investorsEVEvidity Health CapitalLALauder PartnersRHRhapsody Venture PartnersVIVivo CapitalHEHealthQuest CapitalRTRTW Investments L.P.+2 more

Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.

BiotechHealthtechMedical DevicesNew York, US

CAClive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)

BoardKBKristina Burow(Director)in

Co-investorsALAlpha Wave GlobalARARCH Venture PartnersF-F-Prime CapitalGVGV (Google Ventures)RARA CapitalSOSoftBank Vision Fund+4 more

HealthtechWest Lafayette, US

Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)RMRonald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)

Co-investorsECEcoR1 CapitalARArsenal Bridge VentureREREDMILE

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical DevicesBoston, US

LGLuke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)DLDavid Liu, PhD(Founder)ALAngelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)JWJonathan Weissman, PhD

Co-investorsATAtlas VentureNENewpath Partners5A5AM VenturesARARCH Venture PartnersDCDCVC (Data Collective)F-F-Prime Capital+11 more

Parse.ly is a content analytics and audience intelligence platform offering a real-time dashboard, a content recommendation API, a data pipeline to warehouses, and AI-driven insights.

Data & InfrastructureMarketing TechMedia & Entertainment

Co-investorsHAHaatchHOHorizon Technology FinanceSASahsen VenturesSASARAS CAPITALSOSoleus Capital

BiotechFremont, US

AVAvanish Vellanki(Executive Officer)in

Co-investorsBIBiotechnology Value FundSASamsara BioCapital

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

ARAdam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)SRScott Robertson(Executive Officer)inGary Patou(Executive Officer)in

Co-investorsFRFrazier Life SciencesOROrbiMedRARA CapitalSASanofi VenturesSOSofinnova VenturesAGAgent Capital+10 more

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)SMSusan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSASamsara BioCapitalTHThe Column GroupBABain Capital Life SciencesCACanaan PartnersRARA CapitalTCTCG Crossover+2 more

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

VPVishal Patelin

Co-investorsASAscenta CapitalATAtlas VentureBOBorealis VenturesBOBorealis VenturesMAMagnetic VenturesOROrbiMed+3 more

Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.

BiotechCambridge, US

Andrew Ashe(Executive Officer)SKSekar Kathiresan(Executive Officer, Director)inABAndrew Bellinger(Executive Officer)

BoardJohn Evans(Director)APAnthony Philippakis(Director)inKYKrishna Yeshwant(Director)in

Co-investorsARARCH Venture PartnersF-F-Prime CapitalGVGV (Google Ventures)RARA CapitalVEvenBio PartnersCACasdin Capital+3 more

Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.

AI & Machine LearningData & InfrastructureDefense TechTel Aviv

Amiad Daniel(Executive Officer, Director)MPMatan Peled(Director)in

BoardDov Gatmon(Director)Patrick Poon(Director)ESEden Shochat(Director)inThompson Hutton(Director)in

Co-investorsALAlephFTFTV CapitalTHThompson Hutton, LLCPIPivotal Life SciencesQIQiming Venture PartnersQUQuan Capital+3 more

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOROrbiMedQUQuan CapitalRARA CapitalSASanofi VenturesSRSR One Capital ManagementNONovo Holdings+3 more